BioCentury
ARTICLE | Clinical News

Aranesp darbepoetin alfa: Phase III data

June 13, 2005 7:00 AM UTC

In a double-blind, European Phase III trial in 672 patients, 500 µg once every 3 weeks Aranesp was at least as effective as 2.25 µg/kg once weekly from week 5 to the end of the treatment period. Speci...